Segment Information

9 Months Ended

Sep. 30, 2012

Segment Information

Segment Information

12. Segment Information

Following the sale of our telemedicine subsidiary, Medicomp, Inc., and the discontinuation of further telemedicine-related business in 2011, we currently operate as one operating segment. However, we use and regularly review revenues, cost of revenues and gross profit data as a primary measure of performance for each of our three commercial products.

Revenues, cost of revenues and gross profit for each of our commercial products for the three- and nine-month periods ended September 30, 2012 and 2011 were as follows (in thousands):

	Three Months Ended September 30,
2012	Remodulin		Tyvaso		Adcirca		Total
Revenues	$	120,811	$	88,302	$	31,804	$	240,917
Cost of revenues	13,963		11,796		2,209		27,968
Gross profit	$	106,848	$	76,506	$	29,595	$	212,949
2011
Revenues	$	114,918	$	66,330	$	19,772	$	201,020
Cost of revenues	12,659		8,735		1,282		22,676
Gross profit	$	102,259	$	57,595	$	18,490	$	178,344
	Nine Months Ended September 30,
2012	Remodulin		Tyvaso		Adcirca		Total
Revenues	$	341,755	$	239,578	$	84,359	$	665,692
Cost of revenues	43,956		32,073		5,603		81,632
Gross profit	$	297,799	$	207,505	$	78,756	$	584,060
2011
Revenues	$	323,016	$	175,835	$	47,933	$	546,784
Cost of revenues	36,860		23,551		3,166		63,577
Gross profit	$	286,156	$	152,284	$	44,767	$	483,207

For the three-month periods ended September 30, 2012 and 2011, net revenues from our three U.S.-based distributors represented 79 percent and 81 percent, respectively, of our total net operating revenues. For the nine-month periods ended September 30, 2012 and 2011, net revenues from our three U.S.-based distributors represented 79 percent and 82 percent, respectively, of our total net operating revenues.